Core Insights - Shenzhen Precision Medical Technology Co., Ltd. (referred to as "Precision Medical") successfully listed on the Hong Kong Stock Exchange on January 8, marking a significant breakthrough in China's high-end medical equipment sector as the first company to possess multi-port, single-port, and natural orifice surgical robot platforms [1][4] Financing and Investment - Since its establishment in 2017, Precision Medical has completed six rounds of financing, raising over 2 billion yuan (approximately 300 million USD), with investors including Sequoia China, Temasek, and Hillhouse Capital, as well as state-owned funds [1][2] - In 2021, the company raised over 500 million yuan (approximately 75 million USD) in its B round, with a valuation exceeding 1.5 billion USD [2] Investment Philosophy - The investment approach of Liu Tianran, a partner at Xiangfeng Investment, emphasizes understanding clinical needs rather than chasing trends, conducting thorough due diligence in operating rooms, and focusing on companies that create real value [3][4] - Liu was particularly impressed by the founders' deep clinical insights and their ability to address real clinical challenges, aligning with the investment philosophy that values long-term solutions [3] Future Outlook - The future of surgical robots is anticipated to be centered around intelligence, transitioning from "human-assisted" to "machine-assisted" surgeries, with Precision Medical positioned at the forefront of this trend [4] - Liu believes that the next phase of innovation in China will not rely on cost advantages but on achieving systematic breakthroughs in complex clinical environments [4]